Prospective US Study Comparing Thyrotropin Receptor Antibody Assays in Autoimmune Thyroid Disease

Overview

This prospective, blinded study evaluated the clinical performance of four thyrotropin receptor antibody (TSH-R-Ab) assays in 162 patients with various thyroid diseases in the United States. The thyroid-stimulating immunoglobulin (TSI) bioassay demonstrated higher sensitivity for Graves’ disease (GD) detection compared to two automated binding assays, and uniquely identified stimulating versus blocking antibody activity.

Background

Thyrotropin receptor antibodies (TSH-R-Ab) play a central role in the pathophysiology of Graves’ disease by stimulating thyroid hormone production. Historically, assays measuring TSH-R-Ab included laborious bioassays and competitive binding assays, with recent advances producing automated binding assays and functional bioassays for thyroid-stimulating immunoglobulin (TSI) and thyroid-blocking immunoglobulin (TBI). Current clinical guidelines recommend TSH-R-Ab measurement for diagnosis and management of autoimmune hyperthyroidism but do not specify assay type, despite functional differences among antibodies that impact clinical decisions.

Data Highlights

Key Findings

• TSI bioassay showed significantly higher sensitivity (84%) for detecting TSH-R-Ab in Graves’ disease compared to Immulite (65%) and Cobas (63%) binding assays (p<0.0025).
• All 15 newly diagnosed GD patients were positive by TSI bioassay, whereas only 73% were positive by binding assays.
• TSI bioassay detected stimulating antibodies in GD patients with subclinical hyperthyroidism who were negative by binding assays.
• Two GD patients with blocking antibodies (TBI-positive) were negative by TSI bioassay but positive by binding assays, indicating binding assays detect both stimulating and blocking antibodies.
• Binding assays lack specificity for stimulating antibodies and are less sensitive than functional bioassays.
• Functional bioassays provide clinically relevant information by differentiating stimulating from blocking TSH-R antibodies, which may influence management decisions.

Clinical Implications

Measurement of TSH-R-Ab using functional bioassays such as the TSI assay offers superior sensitivity and specificity for detecting stimulating antibodies in Graves’ disease compared to automated binding assays. Clinicians should consider incorporating TSI bioassays into diagnostic and management protocols to better assess antibody functionality, guide treatment decisions, and predict relapse risk. Reliance on binding assays alone may miss clinically relevant antibody activity, particularly in early or subclinical disease.

Conclusion

This US-based prospective study demonstrates that TSI bioassays outperform binding assays in sensitivity and functional specificity for TSH-R-Ab detection in autoimmune thyroid disease. Functional bioassays provide valuable clinical insights that can enhance diagnosis and management of Graves’ disease.

References

1. American Thyroid Association and European Thyroid Association Guidelines -- Recommendations for TSH-R-Ab Measurement
2. FDA-cleared TSI Bioassay Development -- Clinical Utility in Autoimmune Thyroid Disease
3. Comparative Studies of TSH-R-Ab Assays in Europe and Asia -- Prior Retrospective Analyses